ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $42.7M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 3 closing their positions.
120% more capital invested
Capital invested by funds: $19.4M → $42.7M (+$23.3M)
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
44% more call options, than puts
Call options by funds: $32.8M | Put options by funds: $22.9M
13% more funds holding
Funds holding: 24 → 27 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$3.99M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.75M |
| 3 |
Jane Street
New York
|
+$1.86M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.69M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$1.19M |
| 2 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
-$634K |
| 3 |
WSTAM
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
|
-$474K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$218K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$171K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | +$7.35K | +110 | +157% |
|
|
MFS
27
MSI Financial Services
Springfield,
Massachusetts
| $7K | +$6.68K | +100 | New |
|
|
WSTAM
28
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
| – | -$474K | -8,140 | Closed |
|
|
GT
29
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$13K | -230 | Closed |
|
|
BCI
30
Brinker Capital Investments
Berwyn,
Pennsylvania
| – | -$1K | -20 | Closed |
|
BIB Hedge Fund Activity: Q4 2015 in Review
27 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2015, worth a combined $42.7M — up 120% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIB positions and 3 closed out — a net gain of 3 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Virtu Financial, adding an estimated $3.99M. The largest seller was Opus Point Partners Management, cutting an estimated $1.19M.
- 27 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2015, up from 24 in Q3 2015.
- Funds reported $42.7M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2015, up 120% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2015 and 3 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2015 was Virtu Financial, an estimated $3.99M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2015 was Opus Point Partners Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2015.